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Abstract
This study aimed to investigate the effect of supplementation with the probiotic Bifidobac-
terium breve M-16V on the maturation of the intestinal and circulating immune system dur-
ing suckling. In order to achieve this purpose, neonatal Lewis rats were supplemented with
the probiotic strain from the 6th to the 18th day of life. The animals were weighed during the
study, and faecal samples were obtained and evaluated daily. On day 19, rats were eutha-
nized and intestinal wash samples, mesenteric lymph node (MLN) cells, splenocytes and
intraepithelial lymphocytes (IEL) were obtained. The probiotic supplementation in early life
did not modify the growth curve and did not enhance the systemic immune maturation.
However, it increased the proportion of cells bearing TLR4 in the MLN and IEL, and
enhanced the percentage of the integrin αEβ7+ and CD62L+ cells in the MLN and that of
the integrin αEβ7+ cells in the IEL, suggesting an enhancement of the homing process of
naïve T lymphocytes to the MLN, and the retention of activated lymphocytes in the intrae-
pithelial compartment. Interestingly, B. breve M-16V enhanced the intestinal IgA synthesis.
In conclusion, supplementation with the probiotic strain B. breve M-16V during suckling
improves the development of mucosal immunity in early life.
Introduction
The gut-associated lymphoid tissue (GALT) is a very extensive and complex part of the
immune system located in the small intestine and colon. It is organized in inductive sites,
which include isolated lymphoid follicles and Peyer’s Patches (PP), where antigens are sampled
from the lumen by antigen-presenting cells and the synthesis of IgA is stimulated, and the
mesenteric lymph nodes (MLN), where the antigens are presented to naïve lymphocytes which
will become activated cells. After moving to the blood, activated lymphocytes migrate again to
the intestine where they are diffusely distributed in the lamina propria lymphocytes (LPL) and
the intraepithelial lymphocytes (IEL) [1].
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The gut is colonized by intestinal microbiota, composed of hundreds of bacterial species,
which play an important role in the host health. The main functions of the microbiota are pro-
tective, metabolic and trophic activities [2,3]. By producing bacteriocins and also by competing
for nutrients and attachment sites on the intestinal surface, the microbiota protects the host
from pathogen microbes. Furthermore, intestinal bacteria are able to ferment non-digestible
carbohydrates and to produce short-chain fatty acids (SCFA), and they are also involved in
vitamin synthesis and ion absorption. SCFA (such as acetate, propionate and butyrate) are a
source of energy, and also regulate the glucose and lipid metabolism [2,4]. SCFA also have a
trophic effect, promoting the proliferation and differentiation of intestinal epithelial cells. Fur-
thermore, butyrate seems to inhibit neoplastic cell proliferation. Finally, bacteria in the lumen
interact with the immune system through the pattern recognition receptors, such as the toll-
like receptors (TLR), which recognize pathogen-associatedmolecular patterns [5,6].
The host–microbe interaction is of particular importance in early life. The challenge with
antigens is necessary for the maturation of intestine and GALT. The intestinal immune system
will acquire the ability to induce tolerance against innocuous dietary, commensal bacterial and
self-antigens, and to fight pathogen antigens, in order to maintain intestinal homeostasis and
avoid immune-mediated disorders [3,7–9]. Thus, the interaction of microbiota with the intesti-
nal epithelial and immune barriers is involved in the development of oral tolerance and allows
microbiota to modulate both innate and adaptive immunity, locally and systemically.
Probiotics are live microorganisms that confer a health benefit on the host when adminis-
tered in adequate amounts [10]. Different probiotic strains, mainly from Lactobacillus and Bifi-
dobacterium genera [11], have demonstrated beneficial effects in some disorders, such as
diarrhoea, allergy, inflammatory bowel disease (IBD), lactosemalabsorption and necrotizing
enterocolitis (NEC) in preterm neonates [12]. These results evidence that probiotics, are able
to modulate the immune system. Some of the described effects include the modulation of cyto-
kine production by epithelial cells, the increase of mucin secretion, the enhancement of phago-
cytosis and natural killer (NK) cell activity, the activation of T and NKT cells, the stimulation
of IgA production and the reduction of T-cell proliferation [3,5–7,9,13–16]. It has to be taken
into account that each effect is strain-dependent, thus a demonstrated action by particular bac-
teria cannot be attributed to another strain. In this sense, some probiotic strains have shown
pro-inflammatory properties (increasingTh1/Th2 ratio), while others have shown anti-inflam-
matory modulation (decreasingTh1/Th2 ratio). Those stimulating the Th1 cytokine pattern
would be useful in preparing the host to fight against infections, and also to ameliorate allergy.
But they could be harmful in autoimmune diseases [7], where those promoting anti-inflamma-
tory cytokine patterns would be a better option. There are also probiotic strains stimulating
both Th1 and Th2 responses, thus each case needs to be studied individually [7]. The mecha-
nisms of action for this immunomodulation are still not completely known [5,6,13]. Moreover,
host microenvironment and enteric commensals, pathogens and vaccines also contributes to
diversity of response to identical probiotic strains [17,18].
As explained above, early infancy and childhood are a critical period for immune system
programming, and thus they are a window of time of particular interest for the use of probiot-
ics [19,20]. Some authors point out the importance of the establishment of a proper gut micro-
biota, which depends on several factors, such as the mother’s microbiota, the mother’s diet, the
mode of delivery or the use of antibiotics [9,21]. The administration of probiotics to the child
during lactation or after weaning, or even to the mother during pregnancy and lactation, has
been proposed as a strategy to prevent dysbiosis and its harmful consequences [22,23]. An
example of long-term effects is a reduction in the prevalence of attention-deficit hyperactivity
disorder and Asperger’s syndrome in 13-year-old boys who were treated with Lactobacillus
rhamnosus GG (LGG) for the first 6 months of life [24]. Moreover, some effects of the
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probiotics seem to be more potent in the neonatal period, and even lost later in life, i.e. the
modulation of the IgE response [8,9,13]. Hashemi et al. [25] reviewed the recent animal studies
of probiotic supplementation in early life and highlighted some effects, such as the improve-
ment of the microbiota composition, the enhancement of the intestinal maturation and
immune response, and the reduction in the prevalence of infections.
Bifidobacterium breveM-16V is naturally present in infants’ microbiota and has shown
immunomodulatory properties. This probiotic seems to ameliorate allergy symptoms, often in
combination with prebiotics [26–29], and rotavirus diarrhoea [30]. The aim of the present
study was to evaluate the impact of B. breveM-16V supplementation on some aspects of the
immune system development using a neonatal rat as a model. The neonatal rat model is suit-
able for immunonutrition studies, with substantial scientific evidence and an interesting cost-
effective ratio [31]. This model allows the characterization of lymphocyte changes during suck-
ling in several lymphoid compartments [32–35].
Materials and Methods
Animals
Four pregnant Lewis rats (G14), obtained from Janvier Labs (Le-Genest-Saint-Isle, France),
were housed in individual cages, monitored daily and allowed to deliver naturally. The day of
birth was registered as day 1 of life. Litters were unified to 8 pups per lactating dam, with free
access to the nipples and rat diet. Dams were fed a commercial diet corresponding to the Amer-
ican Institute of Nutrition 93G formulation and given water ad libitum. The animals were
housed in controlled conditions of temperature and humidity, in a 12 h:12 h light:dark cycle.
Pups were individually identified. They were weighed and monitored daily in order to obtain
data regarding the influence of the nutritional intervention on growth and faecal features. This
was done after the separation of the pups from their mother, during the handling and before
oral administration.
The studies were approved and performed in accordance with the institutional guidelines
for the care and use of laboratory animals established by the Ethics Committee for Animal
Experimentation of the University of Barcelona and the Catalonian Government (CEEA-UB
Ref.493/12, DAAM: 6905).
Experimental design and dietary supplementation
The first 21 days of a rat’s life corresponds to the lactating 9-month period of humans. The pro-
biotic supplementation began after 1 week of lactation (after the first 1/3 of the period, when
strictly only suckling exists) until the end of the study.
The design chosen was that in which the cells from the immune system compartments are
still in development (age comprised during the suckling period of the animals) [31–37], but
without the interference of breast milk compounds (forcing transition to solid diet on day 17 of
life). Moreover, in order to avoid the transitional trapping lymphocytes effects of weaning on
immune system [38], last day of experiment was performed on day 19, two days after early
weaning.
Suckling rats were distributed into two groups: the reference (REF) and the probiotic (PRO)
groups. Each group was composed of 8 pups from two different litters (just half of the pups
from each litter were used for this study). The PRO group received B. breveM-16V (Morinaga
Milk Industry Co. Ltd, Tokyo, Japan) suspension at a dose of 4.5x108 UFC/100 g of body
weight/day. The REF group was administered with a matched volume of mineral water. Suck-
ling rats were orally administered, as previously described [36], from day 6 to day 18 of age,
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using low-capacity syringes (Hamilton Bonaduz, Bonaduz Switzerland) adapted to forced ali-
mentation tubes of 25 or 23 calibre and 27 mm of length (ASICO, Westmont, IL, USA).
The animals were weighed and faecal samples were collected daily during the study. At the
end of the study intestinal wash samples and spleen and MLN cells and IEL were isolated.
Faecal specimen collection and evaluation
Faecal sampling was performed once daily by gently pressing and massaging the abdomen.
Faecal samples were scored from 1 to 4 (faecal appearance score [FAS]) based on colour, tex-
ture and amount as described: normal faeces (1); soft yellow-green faeces (2); totally loose yel-
low-green faeces (3); high amount of watery faeces (4). Scores 2 indicate diarrhoeic faeces
[37]. Faecal weight for each specimen obtained was also measured.
Spleen and intestinal samples collection
After ketamine/xylazine injection and exsanguination, the abdomen was opened and MLN, the
spleen and the small intestine were collected. The intestine was flushed in situ with cold saline
solution to remove the content. Thereafter the duodenumwas removed. The proximal ¾ por-
tions were used for IEL isolation. The distal ¼ portion of the intestine was used for gut wash
for IgA quantification. It was cut in 5 mm pieces, weighed, and incubated with phosphate
buffer solution for 10 min in a 37°C shaker. After centrifugation, supernatants were stored at
-20°C until analysis [37].
Isolation and purification of spleen and MLN cells and IEL
Spleen and MLN cells were isolated as previously described [39]. IEL suspensions from the
proximal ¾ portion of the intestine were obtained following procedures adapted to neonatal
rats and established previously in our laboratory [32]. They were later purified and cell number
viability was determined using an automated cell counter after staining dead cells with trypan
blue (CountessTM, Invitrogen, Madrid, Spain).
Immunofluorescence staining and flow cytometry analysis
Spleen and MLN cells and IEL (3x105 cells) were stained using immunofluorescence tech-
niques. The mouse anti-rat monoclonal antibody conjugated to fluorescein isothiocyanate,
phycoerythrin, peridinin chlorophyll protein or allophycocyanin used here included anti-CD4
(OX-35), anti-CD8α (OX-8), anti-TCRαβ (R73), anti-TCRγδ (V65) and anti-NKR-P1A (10/
78), all from BD Pharmingen (San Diego, CA, USA); anti-CD45RA (OX-33) from Caltag (Bur-
lingame, CA, USA); anti-CD8β (341) from Serotec (Kidlington, Oxford, UK); anti-TLR4
(76B357.1) from Novus Biologicals (Littleton, CO, USA); anti-αE integrin (OX-62) and anti-
CD62L (OX-85) from BioLegend (San Diego, CA, USA).
For cell subset differentiation four different antibody panels were used: Panel 1: CD45RA/
TLR4/CD8α/CD4; Panel 2: αE integrin/CD62L/CD8α/CD4; Panel 3: TCRαβ/NK/CD8α/CD4
and Panel 4: CD8α/CD8β/TCRγδ. Fist aim was to dissectmain subpopulations. B cells
(CR45RA+ cells, which is a B cell marker in rats) were identifiedwith the first panel. With the
Panel 3 it could be differentiated NK cells (TCRαβ-NK+) fromNKT cells (TCRαβ+NK+), and
also TCRαβ+NK- cells, which in combination with the TCRγδ+ cells (obtained from the Panel
4) constituted the total of T cells. Moreover, the CD8+TCRαβ+NK- cells (Panel 3) plus the
TCRγδ+ cells (Panel 4) could be considered as Tc cells. From Panel 3 we obtained the propor-
tion of Th cells (CD4+CD8-TCRαβ+NK- cells). Panel 1 was designed for investigating the fre-
quency of TLR4+ cells in each of the subsets defined in this panel (CD45RA+, CD4+ or CD8
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+ cells). The αE integrin/CD62Lpattern was studied by Panel 2 in each of the subsets defined
by the combination of the markers used (CD4 and CD8). Gating strategy used in the study can
be observed in the S1 Fig.
Results are expressed as proportion of positive cells for a certainmarker in each particular
subset determined by the combination of other markers with respect to the total lymphocytes
gated (i.e. proportion of TLR4+ cells in CD4+CD8- cells).
Staining was developed following procedures described in previous studies [35], and results
were analysed using a GalliosTM flow cytometer (BeckmanCoulter Inc., Madrid, Spain) in the
cytometry service of the Scientific and Technological Centres of the University of Barcelona
(CCiT-UB). The obtained data were assessed with FlowJo software (Tree Star Inc., Ashland,
OR, USA).
ELISA for intestinal IgA quantification
Gut wash IgA concentration was determined using a sandwich ELISA technique with the Rat
IgA ELISAQuantitation Set (E110-102) from Bethyl Laboratories (Montgomery, TX, USA).
Ninety-six well plates (Nunc MaxiSorp, Wiesbaden, Germany) were coated with adequate dilu-
tion of the capture antibody. After incubating standard or gut wash samples, the peroxidase
conjugated detection antibody was added. Subsequently, substrate solution (3,30,5,50-Tetra-
methylbenzidine plus hydrogen peroxide in dimethyl sulfoxide and 0.05 M phosphate-citrate
buffer, pH 5; Sigma-Aldrich,Madrid, Spain) was added and absorbance was measured at 450
nm, after stopping the enzymatic reaction with 2 MH2SO4, on a microtitre plate photometer
(Labsystems, Helsinki, Finland). Data were interpolated by means of Multiskan Ascent v.2.6
software (Thermo Fisher Scientific S.L.U, Barcelona, Spain). Dilutions of rat IgA (Bethyl
Laboratoires) ranging from 500 to 15.625 ng/mL were used as a standard in each plate. Data
are expressed as ng of IgA per mg of intestinal tissue used for the gut wash.
Statistical analysis
The PASW Statistics 18 software package (SPSS Inc., Chicago, IL, USA) was used for statistical
analysis. Conventional one-way ANOVA test was performed considering the experimental
group as the independent variable. When supplementation had a significant effect on the
dependent variable, Scheffé’s test was applied. Significant differences were accepted when
p<0.05. All the results are expressed as mean ± SEM.
Results
Body weight
The growth curves of the REF and PRO groups were very similar and without statistical differ-
ences throughout the period, as can be seen in Fig 1. Before the PRO intervention (days 3–6),
both groups showed identical weight. From day 6 to day 17 there was a slightly higher weight
in the PRO group, but still similar (p>0.05). On days 18 and 19, the early weaning effect can be
observed in both groups, since there is a slight weight loss during the first days after separation
from their dam.
Faecal consistency
The PRO group showed faecal scores slightly higher than 1 (normal faeces) from the second
day of supplementation (day 8) until day 14, indicating that the PRO induced soft faeces (Fig
2). However, the faecal weight was 7.60 ± 2.90 mg at the beginning of the supplementation and
10.44 ± 1.83 mg at the end for both groups, without significant differences between groups.
Immunomodulation by Bifidobacterium breve M-16V in Early Life
PLOS ONE | DOI:10.1371/journal.pone.0166082 November 7, 2016 5 / 18
Phenotype of spleen and MLN cells and IEL
On the last day of the study (day 19) spleen and MLN cells, as well as IEL, were isolated in
order to evaluate the influence of the PRO on the lymphocytes. A sufficient number of viable
cells from all tissues were obtained (with a viable cell number range of 1.7–4.6x107 and a viabil-
ity of 73–98% for spleen cells; 1.7x105–1.9x106 and 72–91% for MLN cells; 4.5x105–1.1x106
and 76–87% for IEL). No differences were observedbetween the REF and PRO groups.
Main lymphocytesubset proportions. The phenotype of lymphocyte subsets present in
systemic (spleen) and intestinal compartments (MLN and IEL) was studied. The percentage of
the main subsets present in each compartment is summarized in Table 1.
Among the spleen cells, the PRO nutritional intervention did not affect B cell proportion
but was able to significantly reduce the proportion of both T helper (Th) and cytotoxic T (Tc)
cells (p<0.05). However, the administration of the PRO did not influence any of the TCRγδ
+ subtypes, nor the NK or NKT cell proportion. In addition, when the percentage of cells
Fig 1. Rats body weight pattern during the study in the reference (REF) and probiotic (PRO) groups. Results are expressed as mean ± SEM (n = 8
animals/group). The first day of nutritional intervention and the weaning day are shown by arrows.
doi:10.1371/journal.pone.0166082.g001
Immunomodulation by Bifidobacterium breve M-16V in Early Life
PLOS ONE | DOI:10.1371/journal.pone.0166082 November 7, 2016 6 / 18
bearing CD8 co-receptor structure was studied, although a decrease of CD8αβ+ cell proportion
was observeddue to PRO supplementation it did not modify the CD8αα+/CD8αβ+ ratio.
Regarding the MLN, the main subsets proportion (B, Th, Tc, NKT and NK) were not
affected by PRO diet, although an increase in the CD8+ NK population was observed
(p<0.05). Most of the lymphocytes in the MLN with the CD8 co-receptor were CD8αβ+, with
no effect caused by the PRO supplementation.
On the other hand, when the IEL composition was studied, it was observed that the Th cell
proportion was reduced significantly by the nutritional intervention (p<0.05). Although the
Tc cell proportion was not modified, the CD8αβ+TCRγδ+ subset percentage was significantly
reduced (p<0.05). Finally, there was a similar proportion of both CD8αα and CD8αβ IEL in
both groups without any effect from the PRO supplementation. This CD8αα/CD8αβ ratio was
the highest among the three compartments studied.
Fig 2. Faecal appearance score (FAS) in the reference (REF) and probiotic (PRO) groups. Faecal samples were scored from 1 to 4 based
on colour, texture and amount of stool. Scores of FAS 2 indicate diarrhoeic faeces. Results are expressed as mean ± SEM (n = 8 animals/
group).
doi:10.1371/journal.pone.0166082.g002
Immunomodulation by Bifidobacterium breve M-16V in Early Life
PLOS ONE | DOI:10.1371/journal.pone.0166082 November 7, 2016 7 / 18
TLR4 cell surface expression. The ability of developing lymphocytes to interact with bac-
teria was investigated by studying the presence of the TLR4 in the main cell subsets in spleen,
MLN and IEL (Fig 3). The proportion of spleen B cells expressing TLR4 (~20%) was higher
than that in T cells (~10%). No differences in TLR4+ cells were observedbetween the REF and
the PRO groups in the spleen, when explored either in whole lymphocytes or in each cell subset
(Tc, Th or B).
In the MLN, the proportion of B cells presenting TLR4 (~15%) was also higher than that in
T cells (~5%). In this compartment, the proportion of cells bearing TLR4 was higher in the
lymphocytes of the PRO group compared to the REF group. The percentage of TLR4+ cells in
the PRO group was higher in Tc, Th and B lymphocytes than that in the REF group, although
the difference did only achieve statistical significance for the Th cells (p<0.05).
Table 1. Main lymphocyte subsets in the spleen, mesenteric lymph nodes (MLN) and intraepithelial lymphocytes (IEL) of the reference (REF) and
probiotic (PRO) groups.
Spleen MLN IEL
REF PRO REF PRO REF PRO
B cells (CD45RA+) 33.00 ± 1.82 33.60 ± 1.41 12.15 ± 1.57 13.99 ± 0.72 - -
T cells (TCRαβ+NK-
and TCRγδ+)
25.85 ± 0.57 22.32 ± 0.62* 74.78 ± 1.56 70.37 ± 1.69 25.85 ± 0.57 25.85 ± 0.57
Th cells (CD4
+CD8-TCRαβ+)
15.95 ± 0.40 13.55 ± 0.60* 55.43 ± 1.32 52.00 ± 1.45 2.55 ± 0.20 1.58 ± 0.11*
CD4+CD8- 26.11 ± 0.54 23.09 ± 0.49* 59.91 ± 1.58 56.96 ± 1.37 3.35 ± 0.16 2.49 ± 0.14*
CD4+CD8-
TCRαβ-




9.90 ± 0.20 8.77 ± 0.23* 19.35 ± 0.52 18.37 ± 0.62 20.28 ± 0.21 19.33 ± 0.44
TCRαβ+ (CD8
+ TCRαβ+NK-)
8.17 ± 0.24 7.22 ± 0.16* 17.10 ± 0.55 16.21 ± 0.54 8.17 ± 0.60 7.98 ± 0.24
TCRγδ+ 1.73 ± 0.06 1.55 ± 0.09 2.26 ± 0.03 2.16 ± 0.12 12.11 ± 0.77 11.35 ± 0.34
CD8-TCRγδ
+
0.35 ± 0.03 0.29 ± 0.01 0.38 ± 0.02 0.34 ± 0.02 0.66 ± 0.09 0.57 ± 0.06
CD8
+TCRγδ+
1.38 ± 0.04 1.26 ± 0.09 1.88 ± 0.03 1.82 ± 0.11 11.45 ± 0.73 10.78 ± 0.35
CD8αα
+TCRγδ+
0.16 ± 0.02 0.17 ± 0.01 0.21 ± 0.02 0.19 ± 0.04 8.04 ± 0.80 7.89 ± 0.27
CD8αβ
+TCRγδ+
1.21 ± 0.04 1.10 ± 0.08 1.67 ± 0.03 1.62 ± 0.09 3.41 ± 0.16 2.89 ± 0.14*
NKT cells (TCRαβ
+NK+)
2.91 ± 0.06 2.61 ± 0.23 1.81 ± 0.08 1.87 ± 0.16 21.00 ± 0.57 21.06 ± 0.65
NK cells (TCRαβ-NK
+)
7.18 ± 0.19 6.02 ± 0.73 1.18 ± 0.17 1.49 ± 0.15 36.18 ± 0.99 36.89 ± 0.85
CD8+/TCRαβ-
NK+
3.55 ± 0.13 3.23 ± 0.38 0.19 ± 0.02 0.27 ± 0.02* 22.02 ± 0.85 21.29 ± 0.36
CD8αα+ cells 2.49 ± 0.12 2.31 ± 0.24 1.09 ± 0.06 1.27 ± 0.18 21.95 ± 1.49 21.81 ± 0.63
CD8αβ+ cells 10.70 ± 0.11 9.58 ± 0.43* 18.90 ± 0.47 17.49 ± 0.56 21.50 ± 0.61 21.27 ± 0.81
Ratio CD8αα/CD8αβ 0.23 ± 0.01 0.24 ± 0.01 0.06 ± 0.00 0.07 ± 0.01 1.02 ± 0.04 1.03 ± 0.03
Results are expressed as percentage of the total lymphocytes (mean ± SEM, n = 8).
* p<0.05 vs. REF.
doi:10.1371/journal.pone.0166082.t001
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Gut IEL had similar proportions of cells expressing TLR4 in both the REF and PRO groups,
with the exception of the percentage of TLR4+ Th cells, which was higher in the PRO group
(p<0.05).
Cell surface expression of αE integrin and CD62Lmolecules. The lymphocytes’ commit-
ment to the mucosal compartment was studied by means of the proportion of cells expressing two
adhesionmolecules of importance in the intestinal homing (Fig 4). As expected, the αE integrin/
CD62L expression pattern was different among splenocytes,MLN cells and IEL, with CD62L
being highly expressed in organized tissues (spleen andMLN) with respect to IEL, and an inverse
behaviour found for αE integrin (Fig 4). Focusing on the spleen, no changes were found in the
proportion of cells bearingαE integrin and/or CD62L in the REF and PRO groups. The αE
Fig 3. Proportion of TLR4+ cells in the main lymphocyte subsets from the three compartments studied
(spleen, mesenteric lymph nodes and intraepithelial lymphocytes) of the reference (REF) and probiotic
(PRO) groups. Results are expressed as percentage of positive cells in the indicated subset (mean ± SEM, n = 8
animals/group). Statistical differences: *p<0.05 vs. REF.
doi:10.1371/journal.pone.0166082.g003
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integrin/CD62Lpattern was also studied in particular subsets based on the CD4/CD8 cell distri-
bution. In this sense, the proportion of αE+CD62L-,αE+CD62L+,αE-CD62L+ and the
αE-CD62L- cells was studied in the CD4+CD8-, CD4+CD8+,CD4-CD8+ and the CD4-CD8-
subsets and no statistical differenceswere found (Table 2).
In the MLN, cells expressing CD62L were ~ 3-fold more abundant than in the spleen. Integ-
rin αE+ cell proportion was very low in comparison with that in the spleen, and the percentage
of cells expressing αE integrin, either with or without CD62L co-expression, was higher in the
PRO group (0.81 ± 0.06) than in the REF group (0.51 ± 0.06) (p<0.05). When the expression
of these markers was analysed in particular subsets (CD4+, CD8+ and CD4- CD8-), it was
observed that the increase in such a pattern due to the PRO intervention was found in all of
them (Table 2).
Fig 4. αE integrin/CD62L molecular pattern in the total lymphocytes of the spleen, mesenteric lymph
nodes (MLN) and intraepithelial lymphocytes (IEL). Representative histograms for the reference (REF)
and probiotic (PRO) groups are shown. In each quadrant the mean ± SEM (n = 8 animals/group) is included.
Statistical differences: *p<0.05 vs. REF.
doi:10.1371/journal.pone.0166082.g004
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CD62L was almost completely absent on the surface of the IEL but more than 65%
expressed αE integrin. In the PRO group, the integrin αE+ cell proportion (73.95 ± 1.66) was
8% higher than that in the REF group (66.45 ± 1.24) (p<0.05). Again, the increase of integrin
αE+ IEL in the PRO group was found in all CD4+, CD8+ and CD4- CD8- subsets (p<0.05)
and therefore it could not be ascribed to one of these cell types (Table 2).
Intestinal IgA
Intestinal IgA was quantified in gut washes from 19-day-old rats. The administration of the
PRO only during 2 weeks of the suckling period (starting after the first week of life) was enough
to show an enhancing effect on IgA production (Fig 5). In fact, the PRO dietary intervention
increased the intestinal IgA concentration 2-fold (p<0.05).
Discussion
The current study shows that supplementation with the probiotic strain B. breveM-16V during
the rat suckling period influences the lymphocyte composition of both intestinal and systemic
immune compartments, modifies the proportion of cells expressing molecules involved in the
interaction with intestinal bacteria, and also enhances the intestinal antibody synthesis.
In our study, the PRO administration induced no harmful effects because it did not affect
the growth curve. Interestingly, a change in the faecal consistency caused by the PRO was
found. This effect has already been described for some molecules used as probiotic substrate
[40–42], and it is actually beneficial to make faeces more similar to those of breast-fed infants
and to reduce constipation.
During suckling, rats undergo phenotypical changes in lymphoid tissues that are a reflex of
the immune system’s maturation in this period. Thus, immature rat spleen mainly contains B
cells, T, NK and NKT cell proportions that are lower than those in adult rats [32]. As the PRO
supplementation did not produce an increase but rather a decrease in CD4+ and CD8+ cells, it
seems that, apparently, this nutritional intervention does not enhance the systemic immune
maturation. However, when considering the MLN, a secondary lymphoid organ located at
intestinal level and inducer of immune response in this compartment, the PRO
Table 2. Expression of the integrin αE and the selectin CD62L in CD4+, CD8+ and CD4- CD8- patterns in spleen, mesenteric lymph node (MLN)
cells and intraepithelial lymphocytes (IEL) of the reference (REF) and probiotic (PRO) groups.
αE+CD62L- αE+CD62L+ αE-CD62L+ αE-CD62L-
REF PRO REF PRO REF PRO REF PRO
Spleen CD4+CD8- 1.83 ± 0.09 2.01 ± 0.16 0.90 ± 0.12 0.71 ± 0.08 42.23 ± 0.91 41.54 ± 2.34 55.08 ± 0.73 55.73 ± 2.27
CD4+CD8+ 11.56 ± 1.08 12.01 ± 0.52 44.63 ± 1.47 45.67 ± 1.65 16.40 ± 1.38 14.06 ± 1.15 27.40 ± 1.81 28.26 ± 1.27
CD4-CD8+ 1.23 ± 0.12 1.41 ± 0.19 2.42 ± 0.48 2.28 ± 0.21 57.58 ± 2.17 52.66 ± 1.62 38.78 ± 1.89 43.66 ± 1.58
CD4-CD8- 0.87 ± 0.07 0.78 ± 0.03 0.38 ± 0.06 0.27 ± 0.02 17.83 ± 1.89 17.30 ± 0.97 80.95 ± 2.01 81.61 ± 1.00
MLN CD4+CD8- 0.18 ± 0.05 0.24 ± 0.03 0.20 ± 0.05 0.27 ± 0.03 78.73 ± 1.34 77.85 ± 0.60 20.88 ± 1.28 21.65 ± 0.56
CD4+CD8+ 0.24 ± 0.09 1.35 ± 0.35* 1.07 ± 0.23 1.90 ± 0.41 84.63 ± 2.06 81.42 ± 1.18 14.08 ± 2.05 15.35 ± 1.04
CD4-CD8+ 0.47 ± 0.06 0.74 ± 0.11 0.40 ± 0.09 0.51 ± 0.04 77.85 ± 1.37 78.52 ± 0.75 21.30 ± 1.33 20.23 ± 0.63
CD4-CD8- 0.60 ± 0.04 0.86 ± 0.05* 0.29 ± 0.04 0.47 ± 0.06* 59.65 ± 1.79 52.58 ± 2.16* 39.43 ± 1.71 46.08 ± 2.19*
IEL CD4+CD8- 2.21 ± 1.06 6.31 ± 0.73* 0.46 ± 0.30 0.30 ± 0.20 9.00 ± 2.86 8.09 ± 1.91 88.35 ± 2.14 85.30 ± 2.02
CD4+CD8+ 29.09 ± 10.05 33.21 ± 9.21 9.46 ± 5.90 13.81 ± 4.62 11.90 ± 4.31 8.96 ± 2.53 49.55 ± 8.49 44.01 ± 5.03
CD4-CD8+ 93.58 ± 0.57 95.24 ± 0.54 0.52 ± 0.09 0.37 ± 0.04 1.36 ± 0.25 1.00 ± 0.21 4.54 ± 0.53 3.39 ± 0.51
CD4-CD8- 50.20 ± 2.67 60.17 ± 1.80* 0.37 ± 0.07 0.27 ± 0.06 0.38 ± 0.05 0.36 ± 0.04 49.03 ± 2.73 39.19 ± 1.76*
* p<0.05 vs. REF.
doi:10.1371/journal.pone.0166082.t002
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supplementation was able to enhance the proportion of CD8+ NK cells. These cells, although
were found in a low proportion in MLN, are key in the innate immunity [35] and therefore the
current results show that the PRO administration increased this defensive barrier.
With regard to the IEL, these cells are those most in contact with the intestinal lumen and
therefore interventional diets can have major impact on them. This compartment does not
contain B cells, and during suckling there is a progressive increase in the proportion of CD8
+ IEL co-expressing TCRαβ, whereas the percentage of CD8+ cells expressing the NK receptor
decreases [32]. In addition, there is an increase in the proportion of CD4+ cells and TCRγδ
+ cells during the second half of the suckling period [32]. The PRO administration during
suckling did not produce any significant change in the proportion of CD8+ TCRαβ+ IEL or
CD8+ NK cells, but lowered the percentage of CD4+ and the proportion of the particular
CD8αβ+ TCRγδ+ IEL, which are the least abundant in TCRγδ+ cells in the intraepithelial com-
partment. These results agree with Gebert et al. [43] who found a decrease in the CD4+ jejunum
population of neonatal pigs after Lactobacillus brevis supplementation. Some authors also
Fig 5. IgA concentration in intestinal washes of 19-day-old rats from the reference (REF) and probiotic (PRO) groups. Results are
expressed as ng of IgA/mg of tissue (mean ± SEM, n = 8 animals/group). Statistical differences: *p<0.05 vs. REF.
doi:10.1371/journal.pone.0166082.g005
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describe a reduction of CD4+ T cells in the mucosa obtained from patients with Crohn’s dis-
ease when co-culturedwith Lactobacillus casei and Lactobacillus bulgaricus, but no changes
were observed in non-inflamedmucosa [44,45].
In all the three compartments studied, the presence of TLR4 in the main cell subsets was
assessed. The TLR4 receptor recognizes the bacterial lipopolysaccharide. It participates in the
innate immune response against pathogens, but also in the proliferation, differentiation and
development of lymphocytes [46]. TLR4 is essential for the maintenance of the intestinal
homeostasis and barrier function [5,8]. The proportion of splenocytes bearing TLR4 was not
changed by the nutritional intervention but it was increased due to the PRO supplementation
in the CD4+ subset in the MLN and IEL. Therefore, it can be suggested that the PRO can pre-
pare the intestinal immune system for a better response against infections increasing bacteria–
host interaction These results agree with those reported after the administration of Lactobacil-
lus reuteri, L. casei and L. rhamnosus in healthy mice [14,47] and by LGG in healthy rats [48].
However, our findings did not match when TLR4 expression was studied in some pathologies.
In this context, TLR4 expression was decreased by L. reuteri in the intestine of rats with NEC
[49], by L. rhamnosus and Lactobacillus acidophilus in mice with alcoholic liver disease [50],
and also by LGG and other Lactobacillus and Bifidobacterium in the colon of rats with colitis
[48,51].
The circulation is important in leading naïve lymphocytes to find their specific antigen, as
well as for permitting effector or memory lymphocytes to reach infected or inflamed tissue.
Intestinal homing depends on the expression of specific surfacemolecules [52]. The homing of
naïve T lymphocytes in the PP or MLN through the high endothelial venules (HEV) requires
the interaction between the CD62L selectin on the lymphocyte surface and the peripheral node
addressin on the HEV [53]. Moreover, α4β7 integrin is also important to bind to epithelial cells
from the small intestine, and to allow the retention of the IEL [54,55]. Interestingly, the CD62L
and αEβ7 integrin pattern in the MLN cells and the IEL of suckling rats changed after the
administration of B. breveM-16V, which induced a higher percentage of integrin αEβ7+ cells
both in the MLN and the intraepithelial compartment. These results seem to indicate an
enhancement of the homing process of naïve T lymphocytes to the MLN, and the retention of
activated lymphocytes in the IEL compartment [56]. Other studies have evidenced the capacity
of probiotics to modulate homing markers. Lactobacillus plantarum and its excreted peptide
STp have shown stimulation of skin-homingmarkers in vitro, such as cutaneous lymphocyte-
associated antigen (CLA), and a decrease in MadCAM-1 and α4β7 integrin expression in
colonic mucosa in a mouse model of colitis [57–59]. These effects can be useful to attenuate the
intestinal inflammation in IBD. On the other hand, L. casei Shirota failed in modulating the
homing markers on the stimulated T cells by the dendritic cells of patients with ulcerative coli-
tis, but it did increase the CLA skin-homingmarker and β7 gut-homing marker on stimulated
T cells by human dendritic cells from healthy controls [60].
On the other hand, and importantly, the PRO administration for 13 days during the suck-
ling periodwas able to enhance the intestinal IgA synthesis. As expected, the levels of IgA in
the intestinal wash samples of the REF animals were very low [20,33], but B. breveM-16V dou-
bled the intestinal IgA concentration. Since intestinal IgA is a very reliable marker of the muco-
sal defence against pathogens and has been clearly described as a useful tool in
immunonutrition studies [5], this result indicates the immunomodulatory potential of this
probiotic strain. Other studies have reported stimulation of IgA production due to probiotics,
such as LGG [61], Lactobacillus gasseri [9], L. casei, L. reuteri, Bacillus cereus var. Toyoi, Bifido-
bacterium bifidum and Lactobacillus kefiri in mice [23,25,62] or a formula containing Bifido-
bacterium lactis Bb-12 in healthy infants [63].
Immunomodulation by Bifidobacterium breve M-16V in Early Life
PLOS ONE | DOI:10.1371/journal.pone.0166082 November 7, 2016 13 / 18
Finally, it must be considered that in the design of the current study, pups were supple-
mented from day 6 until the end of the study, and were weaned at day 17, a few days after rats
begin to chew solid food. The effects found here demonstrate that supplementation with the
specific strain B. breveM-16V in this short period is enough to show effect, which is in agree-
ment with a study with mice in which just 2 days of supplementation with Lactobacillus del-
brueckii subsp. bulgaricus or L. acidophilus, and 7 days with L.caseiwere necessary to find an
increase of IgA in the LP of the small intestine [5]. However, we cannot discount the possibility
that a new study design with an earlier and longer administration periodwould show more sig-
nificant results.
In summary, the results shown here allow the conclusion to be drawn that the probiotic
intervention during suckling seems to have a low, if any, immune-enhancing effect on the sys-
temic compartment (spleen), but B. breveM16-V administration enhances the ability to
respond against pathogens in both the intestinal inductor (MLN) and effector (IEL) sites and it
promotes the intestinal recruitment and retention of the cells in the epithelial compartment. In
addition, this probiotic strengthens the humoral intestinal immune response. Thus, supple-
mentation with the probiotic strain B. breveM-16V during sucklingmay be helpful in the
development of mucosal immunity in early life.
Supporting Information
S1 Fig. Example of the gating strategy using a mesenteric lymph node lymphocytes’ sample.
A) In Panel 1, B cells (CD45RA+) were identified. The frequency of TLR4+ cells in the B cell
subset was investigated, as well as in CD8+CD4- and CD8-CD4+ subsets. TLR4+ cells were
also quantified in the total gated lymphocytes (not shown). B) In Panel 2, the αE integrin/
CD62L pattern was studied in each of the subsets defined by the combination of the markers
CD4 and CD8.C) In Panel 3, it could be differentiated NK (NK+TCRαβ-) cells from NKT cells
(NK+TCRαβ+), and also NK-TCRαβ+ cells, which in combination with TCRγδ+ cells
(obtained from the Panel 4) constituted the total of T cells. Moreover, the CD8-CD4+ cells in
the NK-TCRαβ+ subset could be considered as Th cells, and the CD8+CD4- cells in this subset
plus the TCRγδ+ cells (Panel 4) could be considered as Tc cells. The proportion of CD8+ cells
in the NK+TCRαβ- subset (NK cells) was also studied.D) In Panel 4, the proportion of
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